Large contemporary data help clarify risk. The TRAVERSE randomized trial followed more than 5,200 hypogonadal men for up to four years and found no significant increase in high-grade or any prostate cancer among those treated with testosterone gel compared with placebo. Prostate events were uncommon in both groups when men were screened and monitored. 

Observational registry work from Sweden, reported in the Journal of Clinical Oncology, found that while men on testosterone had an early uptick in low-risk tumors likely from greater screening, those treated for a year or longer had a lower chance of being diagnosed with aggressive prostate cancer. Independent summaries highlight about a 50 percent reduction in aggressive disease after sustained therapy, a finding that warrants more study but suggests possible risk reduction rather than harm. 

Systematic appraisals from endocrine and urologic societies align with these data: when men are properly evaluated for hypogonadism and monitored with prostate-specific antigen testing and digital rectal exam, testosterone therapy has not been shown to raise prostate cancer incidence. 

One proposed framework is the androgen saturation model. Prostate tissue is highly sensitive to androgens only at very low levels. Once androgen receptors are saturated at physiologic concentrations, additional testosterone has little further stimulatory effect. In men with chronically low testosterone, restoring levels to the normal range may not drive tumor growth and could even improve metabolic health, inflammation, and immune function that influence cancer biology. Reviews in European Urology describe this saturation concept and its clinical implications.  

Epidemiologic analyses also suggest that detection patterns matter. Men who start therapy often undergo more PSA testing and biopsies early, which can uncover indolent, favorable risk lesions. Over a longer follow-up, however, the relative odds shift toward fewer aggressive tumors among treated men. 

The possible protective association has been described in men with documented hypogonadism who maintain therapy for at least a year and who undergo appropriate screening. It does not apply to men with known prostate cancer at high risk for progression or men with very elevated PSA who have not been evaluated by urology. In those special situations, decisions about testosterone must be individualized and often deferred until cancer status is clarified.  

Even with reassuring data, safe prescribing requires structure. The Endocrine Society recommends confirming a low testosterone level, evaluating for causes, and checking PSA and a digital rectal exam before starting therapy. PSA and symptoms should be reassessed within 3 to 12 months and then periodically according to age and risk. This approach minimizes unnecessary biopsies while still detecting clinically important cancers. 

If you have symptoms of low testosterone, such as low energy, reduced libido, depressed mood, or loss of muscle, testing can determine whether you meet criteria for treatment. If hypogonadism is confirmed and you and your healthcare provider decide to proceed with therapy, current evidence suggests you are not increasing your risk of prostate cancer, and sustained treatment may even be associated with a lower likelihood of aggressive disease. This is not a license to skip screening. It is an invitation to treat low testosterone thoughtfully while keeping prostate health front and center.  

Northeast Men’s Health provides expert care in men’s sexual health and provides low testosterone treatment tailored to your needs. We confirm low testosterone, review prostate cancer risk, and check baseline PSA levels. Our team coordinates lifestyle, nutrition, and cardiovascular risk reduction alongside evidence-based testosterone therapy so you can feel better, support long-term health, and stay on top of prostate screening.

If you’re looking for a men’s health provider that offers low-T treatment in New England, contact Northeast Men’s Health today for a consultation. We have locations in Bridgewater, Massachusetts, Dedham, Massachusetts, Marlborough, Massachusetts, Woburn, Massachusetts, Salem, New Hampshire, Farmington, Connecticut, and Warwick, Rhode Island, and we are eager to guide you through low-T treatment and how it can benefit your life.

Contact us today to schedule an appointment.

Disclaimer: Individual results may vary. We cannot guarantee specific outcomes from these services.